869370-01-4

Basic information

• Product Name: 3-methoxy-3-methylbutyl 4-methylbenzenesulfonate
• Synonyms: 3-methoxy-3-methylbutyl 4-methylbenzenesulfonate
• CAS NO: 869370-01-4
• Molecular Weight: 272.365
• Mol File: 869370-01-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-methoxy-3-methylbutyl 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methoxy-3-methylbutyl 4-methylbenzenesulfonate(869370-01-4)
• EPA Substance Registry System: 3-methoxy-3-methylbutyl 4-methylbenzenesulfonate(869370-01-4)

Safety Data

• Hazardous Substances Data: 869370-01-4(Hazardous Substances Data)

Upstream product

• 56539-66-3 solfit 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1268153-93-0 3-methoxy-3-methylbutan-1-amine 

Relevant articles and documents

2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS

Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

This invention relates to 2H-indazole Derivatives of formula (I'), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.